Xtant Medical Q2 revenue falls to $23.0 million; cuts 2026 revenue guidance
Xtant Medical reported a second-quarter 2026 net loss of $9.4 million, compared with net income of $3.6 million a year earlier, as revenue fell to $23.0 million from $35.4 million. The company also lowered its full-year 2026 revenue guidance to $99 million to $103 million from $101 million to $105 million, citing lower-than-expected biologics revenue and amnio product headwinds.
Key points
- Q2 2026 total revenue was $23.0 million versus $35.4 million in Q2 2025; gross margin was 57.9% versus 68.6%.
- Q2 2026 net loss was $9.4 million; non-GAAP adjusted EBITDA loss was $2.7 million versus positive $6.9 million a year earlier.
- Full-year 2026 revenue guidance was cut to $99 million to $103 million from $101 million to $105 million.
- A $5.0 million exclusivity fee paid to Dilon Technologies for a U.S. distribution agreement was written off in the quarter; cash was $9.9 million as of June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.